methyl-CpG binding domain protein 5Genealiases: C2DELq23.1 · DEL2Q23.1 · MRD1
Q-omics provides the consensus-scored MBD5 profile across patient tissues and cancer cell-line models. MBD5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MBD5 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, MBD5 RNA expression shows 22,080 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where MBD5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBD5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBD5 survival associations across molecular data types. MBD5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBD5 RNA expression–survival associations across cancer types. High MBD5 expression shows unfavorable associations in UVM, ACC and KIRP, but favorable associations in KIRC, LGG and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MBD5 RNA expression.
This table summarizes MBD5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MBD5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBD5 shows lower tumor expression in THCA, KICH and BLCA and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher MBD5 RNA expression in normal versus tumor tissue (log2 FC = −0.581, t-test p < 0.001).
This table shows molecular features associated with MBD5 in patient tissues and cancer cell lines. In patient samples, MBD5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MBD5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
